{"id":53255,"date":"2026-01-08T00:23:01","date_gmt":"2026-01-07T16:23:01","guid":{"rendered":"https:\/\/flcube.com\/?p=53255"},"modified":"2026-01-08T00:23:02","modified_gmt":"2026-01-07T16:23:02","slug":"ascentages-protac-btk-degrader-apg-3288-wins-fda-ind-for-b-cell-malignancies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53255","title":{"rendered":"Ascentage&#8217;s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies"},"content":{"rendered":"\n<p><strong>Ascentage Pharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AAPG:NASDAQ\">NASDAQ: AAPG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6855:HKG\">HKG: 6855<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has cleared the <strong>Investigational New Drug (IND)<\/strong> application for <strong>APG-3288<\/strong>, its <strong>original next\u2011generation BTK\u2011targeted protein degrader<\/strong>, enabling clinical studies for <strong>relapsed\/refractory B\u2011cell malignancies<\/strong>. APG-3288 is the <strong>first\u2011in\u2011class BTK degrader<\/strong> developed on Ascentage\u2019s <strong>Proteolysis\u2011Targeting Chimera (PROTAC) platform<\/strong>, designed to overcome resistance to existing BTK inhibitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-product-milestone\">Regulatory &amp; Product Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>APG-3288<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Ascentage Pharma (Nasdaq: AAPG; 6855.HK)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>FDA IND approved<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed\/refractory B\u2011cell malignancies<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>BTK PROTAC degrader (Cereblon E3 ligase)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase\u202fI ready<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First BTK degrader to enter clinical trials globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-protac-degradation-mechanism\">Technology Profile: PROTAC Degradation Mechanism<\/h2>\n\n\n\n<p><strong>Mechanism of Action<\/strong>:<br>APG-3288 facilitates formation of a <strong>ternary complex (BTK\u2011PROTAC\u2011Cereblon E3 ubiquitin ligase)<\/strong>, leading to <strong>proteasome\u2011mediated degradation<\/strong> of BTK protein.<\/p>\n\n\n\n<p><strong>Key Differentiation vs. BTK Inhibitors<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>APG-3288 (PROTAC)<\/th><th>Ibrutinib\/Acalabrutinib (Inhibitors)<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism<\/strong><\/td><td><strong>Degradation<\/strong> (removes protein)<\/td><td><strong>Inhibition<\/strong> (blocks active site)<\/td><\/tr><tr><td><strong>Target Scope<\/strong><\/td><td>Wild\u2011type <strong>and<\/strong> all mutant BTK<\/td><td>Wild\u2011type only; resistance mutants persist<\/td><\/tr><tr><td><strong>Durability<\/strong><\/td><td><strong>Sustained knockdown<\/strong> (days\u2011weeks)<\/td><td>Reversible (requires continuous dosing)<\/td><\/tr><tr><td><strong>Resistance<\/strong><\/td><td><strong>Overcomes C481S, L528W, T474I mutations<\/strong><\/td><td>Clinical resistance drives progression<\/td><\/tr><tr><td><strong>Pathway Blockade<\/strong><\/td><td><strong>Complete signaling shutdown<\/strong> at source<\/td><td>Partial blockade; bypass signaling persists<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Clinical Rationale<\/strong>: By degrading both wild\u2011type and mutant BTK forms, APG-3288 <strong>prevents BCR\u2011BTK signaling reactivation<\/strong>, offering a <strong>differentiated solution<\/strong> for patients who relapse on inhibitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-b-cell-malignancies\">Market Opportunity: B\u2011Cell Malignancies<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global B\u2011Cell Lymphoma\/Incidence<\/strong>: <strong>500,000+<\/strong> new cases annually (CLL, MCL, DLBCL, WM)<\/li>\n\n\n\n<li><strong>China Market<\/strong>: <strong>\u00a545\u202fbillion<\/strong> (2025), growing at <strong>12% CAGR<\/strong><\/li>\n\n\n\n<li><strong>BTK Inhibitor Market<\/strong>: <strong>\u00a518\u202fbillion<\/strong> (2025), dominated by <strong>ibrutinib<\/strong>, <strong>acalabrutinib<\/strong>, <strong>zanubrutinib<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Unmet Need<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>30\u201140%<\/strong> of BTK inhibitor patients develop <strong>resistance<\/strong> within <strong>3\u20115 years<\/strong><\/li>\n\n\n\n<li><strong>No approved therapy<\/strong> for C481S\u2011mutant or other BTK\u2011resistant disease<\/li>\n\n\n\n<li><strong>APB-3288 Target Population<\/strong>: <strong>50,000\u201170,000<\/strong> relapsed\/refractory patients in U.S.\/EU<\/li>\n\n\n\n<li><strong>Peak Sales Potential<\/strong>: <strong>\u00a58\u201112\u202fbillion<\/strong> (US$1.1\u20111.7\u202fbillion) globally by 2032<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Key Limitation<\/th><\/tr><\/thead><tbody><tr><td><strong>APG-3288<\/strong><\/td><td><strong>Ascentage<\/strong><\/td><td>PROTAC BTK degrader<\/td><td><strong>Phase\u202fI<\/strong> (FDA IND cleared)<\/td><td><strong>First\u2011in\u2011class<\/strong><\/td><\/tr><tr><td><strong>Nemtabrutinib<\/strong><\/td><td>Merck<\/td><td>Non\u2011covalent BTK inhibitor<\/td><td>Phase\u202fIII<\/td><td><strong>C481S\u2011mutant activity<\/strong>, reversible<\/td><\/tr><tr><td><strong>Pirtobrutinib<\/strong><\/td><td>Lilly<\/td><td>Non\u2011covalent BTK inhibitor<\/td><td>Phase\u202fIII<\/td><td><strong>C481S\u2011mutant activity<\/strong>, reversible<\/td><\/tr><tr><td><strong>Ibrutinib<\/strong><\/td><td>J&amp;J\/AbbVie<\/td><td>Covalent BTK inhibitor<\/td><td>Marketed<\/td><td><strong>C481S resistance<\/strong><\/td><\/tr><tr><td><strong>Acalabrutinib<\/strong><\/td><td>AstraZeneca<\/td><td>Covalent BTK inhibitor<\/td><td>Marketed<\/td><td><strong>C481S resistance<\/strong><\/td><\/tr><tr><td><strong>Zanubrutinib<\/strong><\/td><td>BeiGene<\/td><td>Covalent BTK inhibitor<\/td><td>Marketed<\/td><td><strong>C481S resistance<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: APG-3288\u2019s <strong>degradation mechanism<\/strong> offers <strong>irreversible removal<\/strong> of both wild\u2011type and mutant BTK, <strong>circumventing all known resistance mutations<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-pathway-amp-financial-outlook\">Development Pathway &amp; Financial Outlook<\/h2>\n\n\n\n<p><strong>Phase\u202fI Design<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population<\/strong>: Relapsed\/refractory CLL\/MCL patients with documented BTK inhibitor resistance<\/li>\n\n\n\n<li><strong>Primary Endpoint<\/strong>: Safety, tolerability, MTD<\/li>\n\n\n\n<li><strong>Secondary<\/strong>: BTK degradation kinetics, ORR (per iwCLL\/Lugano)<\/li>\n\n\n\n<li><strong>Timeline<\/strong>: Initiate Q1\u202f2026; topline data Q4\u202f2026<\/li>\n<\/ul>\n\n\n\n<p><strong>Investment<\/strong>: <strong>\u00a5200\u2011300\u202fmillion<\/strong> (US$28\u201142\u202fmillion) to advance through Phase\u202fII.<\/p>\n\n\n\n<p><strong>Platform Value<\/strong>: APG-3288 validates <strong>Ascentage\u2019s PROTAC platform<\/strong>, enabling <strong>follow\u2011on degrader programs<\/strong> (e.g., <strong>BCL\u20112, IRAK4, STAT3<\/strong>) with <strong>potential for 4\u20116 additional INDs<\/strong> by 2028.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding APG-3288\u2019s clinical development, regulatory pathway, market opportunity, and platform expansion potential. Actual results may differ materially due to clinical trial outcomes, competitive dynamics, and regulatory acceptance of PROTAC technology.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that the U.S. Food and Drug Administration (FDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[200,62,985,3273,70],"class_list":["post-53255","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ascentage-pharma","tag-clinical-trial-approval-initiation","tag-hkg-6855","tag-nasdaq-aapg","tag-tpd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascentage&#039;s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for APG-3288, its original next\u2011generation BTK\u2011targeted protein degrader, enabling clinical studies for relapsed\/refractory B\u2011cell malignancies. APG-3288 is the first\u2011in\u2011class BTK degrader developed on Ascentage\u2019s Proteolysis\u2011Targeting Chimera (PROTAC) platform, designed to overcome resistance to existing BTK inhibitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53255\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage&#039;s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies\" \/>\n<meta property=\"og:description\" content=\"Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for APG-3288, its original next\u2011generation BTK\u2011targeted protein degrader, enabling clinical studies for relapsed\/refractory B\u2011cell malignancies. APG-3288 is the first\u2011in\u2011class BTK degrader developed on Ascentage\u2019s Proteolysis\u2011Targeting Chimera (PROTAC) platform, designed to overcome resistance to existing BTK inhibitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53255\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T16:23:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T16:23:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53255#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53255\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascentage&#8217;s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies\",\"datePublished\":\"2026-01-07T16:23:01+00:00\",\"dateModified\":\"2026-01-07T16:23:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53255\"},\"wordCount\":534,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascentage Pharma\",\"Clinical trial approval \\\/ initiation\",\"HKG: 6855\",\"NASDAQ: AAPG\",\"TPD\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53255#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53255\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53255\",\"name\":\"Ascentage's PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-07T16:23:01+00:00\",\"dateModified\":\"2026-01-07T16:23:02+00:00\",\"description\":\"Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for APG-3288, its original next\u2011generation BTK\u2011targeted protein degrader, enabling clinical studies for relapsed\\\/refractory B\u2011cell malignancies. APG-3288 is the first\u2011in\u2011class BTK degrader developed on Ascentage\u2019s Proteolysis\u2011Targeting Chimera (PROTAC) platform, designed to overcome resistance to existing BTK inhibitors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53255#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53255\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53255#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage&#8217;s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascentage's PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies - Insight, China&#039;s Pharmaceutical Industry","description":"Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for APG-3288, its original next\u2011generation BTK\u2011targeted protein degrader, enabling clinical studies for relapsed\/refractory B\u2011cell malignancies. APG-3288 is the first\u2011in\u2011class BTK degrader developed on Ascentage\u2019s Proteolysis\u2011Targeting Chimera (PROTAC) platform, designed to overcome resistance to existing BTK inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53255","og_locale":"en_US","og_type":"article","og_title":"Ascentage's PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies","og_description":"Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for APG-3288, its original next\u2011generation BTK\u2011targeted protein degrader, enabling clinical studies for relapsed\/refractory B\u2011cell malignancies. APG-3288 is the first\u2011in\u2011class BTK degrader developed on Ascentage\u2019s Proteolysis\u2011Targeting Chimera (PROTAC) platform, designed to overcome resistance to existing BTK inhibitors.","og_url":"https:\/\/flcube.com\/?p=53255","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T16:23:01+00:00","article_modified_time":"2026-01-07T16:23:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53255#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53255"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascentage&#8217;s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies","datePublished":"2026-01-07T16:23:01+00:00","dateModified":"2026-01-07T16:23:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53255"},"wordCount":534,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascentage Pharma","Clinical trial approval \/ initiation","HKG: 6855","NASDAQ: AAPG","TPD"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53255#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53255","url":"https:\/\/flcube.com\/?p=53255","name":"Ascentage's PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-07T16:23:01+00:00","dateModified":"2026-01-07T16:23:02+00:00","description":"Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for APG-3288, its original next\u2011generation BTK\u2011targeted protein degrader, enabling clinical studies for relapsed\/refractory B\u2011cell malignancies. APG-3288 is the first\u2011in\u2011class BTK degrader developed on Ascentage\u2019s Proteolysis\u2011Targeting Chimera (PROTAC) platform, designed to overcome resistance to existing BTK inhibitors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53255#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53255"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53255#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage&#8217;s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53255"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53255\/revisions"}],"predecessor-version":[{"id":53257,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53255\/revisions\/53257"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}